Hemogenyx Pharmaceuticals Plc (HOPHF)
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments. Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies. Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.
Sector: Biotechnology
Industry: Biotechnology
Hemogenyx Pharmaceuticals Plc
- 0.0%
- 1.2K
- 999.99
Float 3.88M · FMP free float
The cost to borrow HOPHF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 1.2K sh |
| Oct 15, 2026 | 1.2K sh |
| Sep 30, 2026 | 1.1K sh |
| Sep 15, 2026 | 105 sh |
| Feb 27, 2026 | 117 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for HOPHF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 1,164 HOPHF shares were sold short (0.03% of a 3.88M-share float, 999.99 days to cover).